The Vibrazine Is used for the treatment of nausea, vomiting and dizziness associated with disorders in the vestibular system. Vibazine is the trade name that receives buclizine hydrochloride distributed by the Pfizer laboratory (Pfizer, 2016).
After several years of disuse, the use of vibrazine has become popular thanks to several campaigns run by the drug labs that distribute buclizine hydrochloride.
Vibazin is currently promoted primarily as an appetite stimulant for individuals with low weight, an antihistamine and an antiemetic.
As an antiemetic, vibrazine reduces dizziness and nausea, regulating the functions of the vestibular system. As an antihistamine this medication reduces allergies, it has also been proven successful as an analgesic in the treatment of migraines, insomnia and some types of diabetes.
Vibrazine syrup is marketed as an appetite stimulant especially for children with nutritional deficiencies. Although it has always been promulgated as an appetite stimulant, it is only in the last twenty years that the laboratories have decided to promote this medicine with scientific support, proving its efficacy.
Although vibain is primarily marketed as an appetite stimulant, there is no current study on these qualities of the drug.
Likewise, no scientific paper has been published on vibazine for more than twenty years and no pharmacological information is available to indicate that buclizine hydrochloride is an appetite stimulant.
Uses of buclizine hydrochloride or vibrazine
Buclizine hydrochloride is a salt derived from piperazine primarily used as anti-vertigo and antiemetic. Buclazine is mainly used in the prevention and treatment of nausea, vomiting and discomfort related to disorders of the vestibular system (Gaillard, 1955).
The complete uses of buclizine hydrochloride have not yet been fully elucidated, however, the anticholinergic effects of buclazine as a blocker of impulses directed to the parasympathetic system through the nerves have been demonstrated in different studies.
This medication is also widely used as an antihistamine, central nervous system suppressor and local anesthetic (Settel, 1959). Some of the effects most commonly seen in patients taking buclizine hydrochloride include the following:
- Decreased vestibular stimulation: Vibrazine has been found to exert an effect on the reduction of stimuli to the vestibular system, which contributes to the conservation of balance and prevents the patient from feeling dizzy or discomfort caused by the movement
- Reduction in labyrinthine functions: patients treated with vibrazine with less likely to experience dizziness or balance problems occasioned when labyrinthine functions fail.
Vibrazine serves essentially as an ideal medicament for reducing over stimulation of the vestibular apparatus that sends signals to the center of the vomit located in the medullary part of the brain .
Disorders in the vestibular system generally produce emesis or vomiting, and vibain serves to reduce physiological activities that send stimuli to receptors located in the center of the vomit (Association, 1992).
Vibazine as an appetite stimulant
Originally Vibcine is an antihistamine that has been widely used as an anti-emetic for decades and even as an analgesic in the treatment of migraines. However, it is also used as an appetite stimulant comparable to Cyproheptadine.
Vibrazine is used to improve the absorption of food in the body without affecting the hormonal levels of it. This means that it is in pregnant patients that vibain will not affect the embryonic development nor the production of hormones necessary for gestation (F J & NESBITT, 1958).
Unlike other appetite stimulants, once the consumption of vibrazine is suspended the weight gained during use tends to remain (Pharmacol, 2011).
In order for the effects of adult vibain to be visible it is recommended to consume 50 to 150 mg of buclizine hydrochloride daily divided into three doses. The amount to be administered in infants should be determined by the treating physician.
It is important to avoid consuming more than the amount prescribed by the doctor. This in order to avoid intoxication and other harmful effects to the body caused by possible poisoning.
In the event of such intoxication, the patient should go to the nearest hospital with the packaging of the vibranin so the treating physician can analyze the medication.
Likewise, it should be clarified that for the vibrazine to fulfill its functions must be in perfect condition, keeping in a dry and cool space, away from direct light or high temperatures.
Vibrio Side Effects
Despite the multiple uses of vibrazine, its consumption can generate some side effects. These effects may appear, however, do not always affect patients treated with this drug (Drugs.com, 1996). Patients who exhibit any of the following side effects should consult their physician:
- Blurry vision
- Dry mouth, nose, and throat
- Nervousness and anxiety
- Gastric pains
- Fluid retention
Precautions in the use of vibain
Vibrazine is a rapidly absorbed oral medication. It is recommended to have some precautions in their consumption since certain health conditions of certain patients can lead them to have hypersensitivity to the drug and to the appearance of side effects.
On the other hand, once the consumption of buclizine hydrochloride is started the patients should be constant with their intake, otherwise the effects of the medication will not be visible.
It is recommended to place the vibain in a visible place where you walk every day, like the kitchen or the bathroom, this will avoid forgetting your consumption. The use of alarms as reminders to take the vibe is also recommended.
It is important to keep in mind that Vibrazine is a drug that is metabolized by the liver and that the ingestion of alcohol or other suppressants of the central nervous system can affect the body's motor functions by intensifying the effects of vibain.
- Association, A.M. (1992). Drug evaluations subscription , 414.
- com. (3 of 1 of 1996). Drugs.com . Retrieved from Buclizine (Systemic): drugs.com
- F J, C., & Nesbitt, E. R. (1958). Buclizine Hydrochloride for Nausea and Vomiting of Pregnancy. Obstetrics & Gynecology, Volume 11 - Issue 2 , 214-219.
- Gaillard, G. (1955). Clinical evaluation of a new antihistamine, buclizine hydrochloride (Vibazine). Journal of Allergy, Volume 26, Issue 4 , 373-376.
- Pfizer, L. (1 of 4, 2016). My Vademecum . Retrieved from"Vivazina"- Pfizer Lab: mivademecum.com.
- Pharmacol, J. J. (4 of 2011). US National Library of Medicine . Obtained from Buclizine is back again! This time as a pediatric appetite stimulant: ncbi.nlm.nih.gov.
- Settel, E. (1959). Buclizine, A New Tranquilizing Agent. Journal of The American Geriatrics Society , 67.